Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
48 shown of 9,293 total abstracts
  1. Abstract 93942026-04-01 · 14:45 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    H. Rugo, E. Winer, C. Saura, et al. · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  2. Abstract 92632026-04-03 · 15:15 CT · E450
    CheckMate-742: Opdivo (nivolumab) adjuvant in NSCLC
    M. Reck, J. Brahmer · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract 97652026-04-04 · 13:30 CT · E450
    FLAURA-6: Tagrisso (osimertinib) adjuvant in NSCLC
    M.C. Garassino, G. Curigliano · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 94382026-04-03 · 18:30 CT · S100A
    CheckMate-287: Opdivo (nivolumab) adjuvant in NSCLC
    G. Curigliano, R. Herbst, M. Krop · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 93792026-04-02 · 21:30 CT · S406
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-297
    M. Krop, P. Schmid, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract 94382026-04-02 · 20:15 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-391 study)
    H. Borghaei, S. Antonia, J. Cortes, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract 97582026-04-04 · 15:45 CT · Hall B1
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-727
    P. Schmid, A. Spira · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 93272026-04-05 · 21:30 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-228
    J. Brahmer, P. Schmid, J. Cortes · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  9. Abstract 93162026-04-03 · 13:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-439
    S. Modi, L. Paz-Ares, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 90542026-04-01 · 13:30 CT · E450
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    M. Krop, E. Winer, C. Saura, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 91742026-04-04 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-636 study)
    P. Schmid, M. Reck, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  12. Abstract 96732026-04-04 · 18:45 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-753 study)
    H. Rugo, M. Reck · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract 98772026-04-01 · 18:45 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-679
    G. Curigliano, J. Cortes, J. Brahmer, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract 97962026-04-03 · 15:00 CT · S406
    Long-term follow-up of Keytruda adjuvant for SCLC: KEYNOTE-151
    C. Robert, H. Borghaei, L. Paz-Ares, et al. · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  15. Abstract 93992026-04-01 · 19:00 CT · S100A
    FLAURA-476: Tagrisso (osimertinib) adjuvant in NSCLC
    S. Peters, L. Paz-Ares, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 90052026-04-02 · 18:15 CT · E450
    Quality of life outcomes with Imfinzi in patients with SCLC
    M. Krop, C. Robert, C. Saura · Peter MacCallum Cancer Centre
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  17. Abstract 93782026-04-05 · 14:00 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-719 study)
    L. Paz-Ares, A. Spira, C. Saura, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  18. Abstract 96352026-04-05 · 16:00 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-514
    A. Spira, N. Rizvi, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 94902026-04-02 · 15:15 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-942
    M.C. Garassino, S. Peters · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 95912026-04-01 · 20:00 CT · S406
    Quality of life outcomes with Tecentriq in patients with NSCLC
    R. Herbst, H. Borghaei, S. Antonia · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract 91702026-04-04 · 16:15 CT · Hall B1
    CheckMate-369: Opdivo (nivolumab) maintenance in NSCLC
    N. Rizvi, F. Andre, S. Peters, et al. · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 90362026-04-01 · 20:00 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-300
    J. Cortes, G. Curigliano, J. Brahmer, et al. · Massachusetts General Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 94092026-04-02 · 16:45 CT · S406
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-282 study)
    P. Schmid, R. Herbst, S. Antonia, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  24. Abstract 96242026-04-02 · 13:45 CT · S406
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-76 study)
    H. Borghaei, L. Paz-Ares, C. Saura, et al. · Royal Marsden Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 99322026-04-03 · 16:00 CT · S100A
    Long-term follow-up of Keytruda adjuvant for NSCLC: KEYNOTE-27
    S. Peters, S. Tolaney · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 96432026-04-05 · 18:00 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-351
    T. Mok, F. Andre · University of Chicago
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 98982026-04-04 · 19:00 CT · E450
    PACIFIC-436: Imfinzi (durvalumab) adjuvant in SCLC
    M. Krop, N. Rizvi · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  28. Abstract 93722026-04-05 · 15:30 CT · S100A
    Quality of life outcomes with Keytruda in patients with NSCLC
    T. Mok, H. Rugo · Mayo Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 94282026-04-01 · 16:30 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    C. Saura, T. Mok, R. Herbst, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 90882026-04-04 · 13:00 CT · Hall B1
    IMpower-123: Tecentriq (atezolizumab) adjuvant in NSCLC
    M. Reck, H. Borghaei, T. Mok, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  31. Abstract 90812026-04-01 · 13:30 CT · S406
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-74
    S. Antonia, A. Spira, S. Modi · Peter MacCallum Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  32. Abstract 91252026-04-04 · 19:15 CT · Arie Crown Theater
    DESTINY-Breast-995: Enhertu (trastuzumab deruxtecan) neoadjuvant in NSCLC
    R. Herbst, P. Schmid, T. Mok · Mayo Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  33. Abstract 94872026-04-01 · 19:00 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    T. Mok, F. Andre · Chinese University of Hong Kong
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  34. Abstract 93012026-04-05 · 18:00 CT · E450
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-85 study)
    J. Brahmer, G. Curigliano, H. Borghaei · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  35. Abstract 97092026-04-04 · 15:30 CT · Arie Crown Theater
    PACIFIC-63: Imfinzi (durvalumab) 3L+ in NSCLC
    P. Schmid, N. Rizvi, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  36. Abstract 97262026-04-03 · 15:45 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-643 study)
    T. Mok, E. Winer · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  37. Abstract 94932026-04-05 · 21:15 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    M. Krop, S. Modi, E. Winer, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 91262026-04-05 · 21:45 CT · Hall B1
    CheckMate-587: Opdivo (nivolumab) maintenance in NSCLC
    T. Mok, M.C. Garassino, J. Brahmer, et al. · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  39. Abstract 98832026-04-05 · 19:45 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    S. Peters, P. Schmid, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  40. Abstract 95612026-04-04 · 18:15 CT · S100A
    Long-term follow-up of Tecentriq adjuvant for NSCLC: IMpower-742
    J. Brahmer, A. Spira, P. Schmid · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  41. Abstract 90892026-04-03 · 15:15 CT · S406
    Long-term follow-up of Keytruda 2L for SCLC: KEYNOTE-662
    M. Reck, S. Peters, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  42. Abstract 96592026-04-05 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-14 study)
    A. Spira, C. Saura, M. Krop, et al. · Royal Marsden Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  43. Abstract 94482026-04-02 · 14:00 CT · E450
    Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-966
    S. Modi, S. Antonia, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 97582026-04-04 · 13:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-141
    J. Cortes, N. Rizvi · Princess Margaret Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  45. Abstract 99802026-04-05 · 13:30 CT · S100A
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-145
    S. Peters, S. Antonia, A. Spira · National Cancer Center Japan
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  46. Abstract 90272026-04-01 · 21:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-523 study)
    A. Spira, H. Rugo · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  47. Abstract 92832026-04-03 · 13:15 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-415 study)
    G. Curigliano, L. Paz-Ares, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  48. Abstract 94802026-04-05 · 18:15 CT · E450
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-537
    J. Brahmer, L. Paz-Ares · Stanford Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.